Singulair is a widely registered brand within the category of drugs for obstructive airway diseases, marketed in 62 countries across both established and emerging healthcare systems. Its active ingredient is montelukast, a medication with anti-inflammatory and anti-bronchoconstrictive properties used in chronic respiratory and allergic conditions. The page is intended for travellers, expatriates, and family members trying to identify or continue this therapy across borders.
Montelukast is prescribed in the management of asthma, allergic rhinitis, hay fever, and exercise-induced bronchoconstriction. It is generally positioned as a long-term controller medication taken regularly to manage underlying inflammatory pathways, distinct from the rescue inhalers that asthma patients use for acute symptomatic relief. The structured indication list further down this page details the registered uses recognised across the markets where Singulair is authorised.
Because Singulair is so broadly distributed, travellers and expatriates frequently encounter it abroad — sometimes under the Singulair name, sometimes as a montelukast-containing generic. Markets where the brand is registered include Australia, Brazil, Canada, Austria, and China, but regulatory pathways, packaging, and prescription requirements vary considerably from one country to another. A local pharmacist can confirm whether a montelukast product on the shelf is the appropriate equivalent of the prescription a patient is used to receiving at home.
Other medications used in obstructive airway disease and allergic rhinitis are sold in many of the same markets under different molecules and brand names, although they occupy distinct therapeutic roles and are not freely interchangeable. Anyone managing long-term respiratory or allergic therapy while travelling should treat any substitution as a clinical conversation rather than a pharmacy-counter decision, with input from a healthcare provider familiar with the patient's history.
